Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules

Overview

Journal Endocrinol Metab (Seoul)

Specialty Endocrinology

Date 2016 Nov 12

PMID 27834083

Citations 5

Authors

Hyemi Kwon

Won Gu Kim

Markus Eszlinger

Ralf Paschke

Dong Eun Song

Mijin Kim

Suyeon Park

Min Ji Jeon

Tae Yong Kim

Young Kee Shong

Won Bae Kim

Affiliations

Soon will be listed here.

Abstract

Background: Molecular analysis for common somatic mutations in thyroid cancer can improve diagnostic accuracy of fine-needle aspiration cytology (FNAC) in the nondiagnostic or indeterminate category of thyroid nodules. In this study, we evaluated the feasibility of molecular diagnosis from residual liquid-based cytology (LBC) material after cytological diagnosis.

Methods: This prospective study enrolled 53 patients with thyroid nodules diagnosed as nondiagnostic, atypia of undetermined significance (AUS), or follicular lesion of undetermined significance (FLUS) after FNAC. DNAs and RNAs were isolated from residual LBC materials. BRAF(V600E) and RAS point mutations, PAX8/peroxisome proliferator-activated receptor γ (PPARγ), RET/PTC1, and RET/PTC3 rearrangements were evaluated by real-time polymerase chain reaction and pyrosequencing.

Results: All DNAs from 53 residual LBC samples could be analysed and point mutations were detected in 10 samples (19%). In 17 AUS nodules, seven samples (41%) had point mutations including BRAF (n=4), NRAS (n=2), and KRAS (n=1). In 20 FLUS nodules, three samples (15%) had NRAS point mutations. RNA from only one FLUS nodule could be analysed for rearrangements and there was no abnormality.

Conclusion: Molecular analysis for BRAF and RAS mutations was feasible in residual LBC materials and might be useful for diagnosis of indeterminate thyroid nodules.

Citing Articles

Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer.

Itonaga M, Ashida R, Murata S, Yamashita Y, Hatamaru K, Tamura T Cancers (Basel). 2022; 14(3).

PMID: 35158819 PMC: 8833456. DOI: 10.3390/cancers14030551.

K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma.

Sekita-Hatakeyama Y, Nishikawa T, Takeuchi M, Morita K, Takeda M, Hatakeyama K PLoS One. 2018; 13(3):e0193692.

PMID: 29494669 PMC: 5832306. DOI: 10.1371/journal.pone.0193692.

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm.

Oh H, Kwon H, Park S, Kim M, Jeon M, Kim T Endocrinol Metab (Seoul). 2018; 33(1):62-69.

PMID: 29388401 PMC: 5874197. DOI: 10.3803/EnM.2018.33.1.62.

Articles in Endocrinology and Metabolism in 2016.

Lee W Endocrinol Metab (Seoul). 2017; 32(1):62-67.

PMID: 28345318 PMC: 5368124. DOI: 10.3803/EnM.2017.32.1.62.

Loss of c-KIT expression in thyroid cancer cells.

Franceschi S, Lessi F, Panebianco F, Tantillo E, La Ferla M, Menicagli M PLoS One. 2017; 12(3):e0173913.

PMID: 28301608 PMC: 5354407. DOI: 10.1371/journal.pone.0173913.

References

Gilbert L, Oates E, Ratnam S . Stability of cervical specimens in SurePath medium for human papillomavirus testing with the Roche cobas 4800 assay. J Clin Microbiol. 2013; 51(10):3412-4. PMC: 3811638. DOI: 10.1128/JCM.01391-13. View

Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. DOI: 10.1210/er.2007-0007. View

Michael C, McConnel J, Pecott J, Afify A, Al-Khafaji B . Comparison of ThinPrep and TriPath PREP liquid-based preparations in nongynecologic specimens: a pilot study. Diagn Cytopathol. 2001; 25(3):177-84. DOI: 10.1002/dc.2033. View

Kim J . Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma. Endocrinol Metab (Seoul). 2014; 29(3):211-6. PMC: 4192816. DOI: 10.3803/EnM.2014.29.3.211. View

Eszlinger M, Paschke R . Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol. 2010; 322(1-2):29-37. DOI: 10.1016/j.mce.2010.01.010. View

Cibas E, Ali S . The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009; 19(11):1159-65. DOI: 10.1089/thy.2009.0274. View

Nikiforova M, Nikiforov Y . Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009; 19(12):1351-61. DOI: 10.1089/thy.2009.0240. View

Hong A, Lim J, Kim T, Choi H, Yoo W, Min H . The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades. Endocrinol Metab (Seoul). 2014; 29(4):505-13. PMC: 4285045. DOI: 10.3803/EnM.2014.29.4.505. View

Rehfeld C, Munz S, Krogdahl A, Jensen E, Siebolts U, Ferraz C . Impact of different methodologies on the detection of point mutations in routine air-dried fine needle aspiration (FNA) smears. Horm Metab Res. 2013; 45(7):513-7. DOI: 10.1055/s-0033-1337987. View

10.

Crippa S, Mazzucchelli L, Cibas E, Ali S . The Bethesda System for reporting thyroid fine-needle aspiration specimens. Am J Clin Pathol. 2010; 134(2):343-4. DOI: 10.1309/AJCPXM9WIRQ8JZBJ. View

11.

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

12.

Xing M, Tufano R, Tufaro A, Basaria S, Ewertz M, Rosenbaum E . Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004; 89(6):2867-72. DOI: 10.1210/jc.2003-032050. View

13.

Srinivasan M, Sedmak D, Jewell S . Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002; 161(6):1961-71. PMC: 1850907. DOI: 10.1016/S0002-9440(10)64472-0. View

14.

Nikiforov Y, Steward D, Robinson-Smith T, Haugen B, Klopper J, Zhu Z . Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94(6):2092-8. DOI: 10.1210/jc.2009-0247. View

15.

Rossi E, Martini M, Capodimonti S, Straccia P, Cenci T, Lombardi C . Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol. 2013; 168(6):853-9. DOI: 10.1530/EJE-13-0023. View

16.

Xing M, Haugen B, Schlumberger M . Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013; 381(9871):1058-69. PMC: 3931461. DOI: 10.1016/S0140-6736(13)60109-9. View

17.

Krane J, Cibas E, Alexander E, Paschke R, Eszlinger M . Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity. Cancer Cytopathol. 2015; 123(6):356-61. DOI: 10.1002/cncy.21546. View

18.

VANDER J, Gaston E, DAWBER T . The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968; 69(3):537-40. DOI: 10.7326/0003-4819-69-3-537. View

19.

Yip L . Molecular diagnostic testing and the indeterminate thyroid nodule. Curr Opin Oncol. 2013; 26(1):8-13. DOI: 10.1097/CCO.0000000000000023. View

20.

Musholt T, Fottner C, Weber M, Eichhorn W, Pohlenz J, Musholt P . Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg. 2010; 34(11):2595-603. DOI: 10.1007/s00268-010-0729-4. View